Change search
ReferencesLink to record
Permanent link

Direct link
The diflunisal trial: study accrual and drug tolerance
Umeå University, Faculty of Medicine, Department of Public Health and Clinical Medicine, Medicine.
Show others and affiliations
2012 (English)In: Amyloid: Journal of Protein Folding Disorders, ISSN 1350-6129, Vol. 19, no S1, 37-38 p.Article in journal (Refereed) Published
Abstract [en]

Familial amyloidotic polyneuropathy (FAP) is a protein folding disorder that induces neuropathy and cardiomyopathy, leading to death within 7-15 years after onset of clinical disease. In vitro, small ligands binding the thyroid hormone docking site stabilize tetrameric transthyretin, inhibiting amyloid fibril formation. We undertook a randomized, placebo-controlled clinical trial to determine whether diflunisal, a well-known non-steroidal anti-inflammatory drug (NSAID) alters neurologic disease progression in FAP. We enrolled 130 subjects with wide age and FAP mutation representation. To date, few recognized complications of NSAIDs have occurred in the study cohort. Data collection will be completed by November 2012.

Place, publisher, year, edition, pages
2012. Vol. 19, no S1, 37-38 p.
Keyword [en]
Clinical trials, diflunisal, FAP, neuropathy, transthyretin
National Category
Family Medicine
URN: urn:nbn:se:umu:diva-56404DOI: 10.3109/13506129.2012.678509ISI: 000304406400013OAI: diva2:535589
Available from: 2012-06-20 Created: 2012-06-18 Last updated: 2012-06-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Suhr, Ole B
By organisation
In the same journal
Amyloid: Journal of Protein Folding Disorders
Family Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 97 hits
ReferencesLink to record
Permanent link

Direct link